

COMPUTATIONAL MODELS AND METHODS FOR PREDICTING CANCER PROGRESSION AND TREATMENT RESPONSE

TRACK NUMBER 300 - BIOMECHANICS AND MECHANOBIOLOGY

GUILLERMO LORENZO^{1,3}, RYAN WOODALL², DAVID A. HORMUTH II³, MICHAEL R. A.
ABDELMALIK⁴, RUSSELL C. ROCKNE², ALESSANDRO REALI¹, THOMAS E. YANKEELOV³,
THOMAS J. R. HUGHES³

¹Department of Civil Engineering and Architecture, University of Pavia
Via Ferrata 3, 27100 Pavia, Italy

Email: guillermo.lorenzo@unipv.it, alessandro.reali@unipv.it

²Department of Computational and Quantitative Medicine, City of Hope
1500 East Duarte Road, Duarte, CA 91010, USA

E-mail: rrockne@coh.org, rwoodall@coh.org

³Oden Institute for Computational Engineering and Sciences, The University of Texas at Austin
201 E. 24th Street, Austin, TX 78712-1229, USA

Email: david.hormuth@utexas.edu, thomas.yankeelov@utexas.edu, hughes@oden.utexas.edu

⁴Department of Mechanical Engineering, Eindhoven University of Technology
Groene Loper 15, 5612 AE Eindhoven, The Netherlands.

Email: m.abdel.malik@tue.nl

Key words: cancer, computational oncology, cancer forecasting, mechanistic modeling, machine learning, inverse problems, uncertainty quantification, model selection, optimal control theory, digital twins

ABSTRACT

Cancers are highly heterogeneous diseases that involve diverse biological mechanisms, interacting and evolving at various spatial and temporal scales. Multiple experimental, histopathological, clinical, and imaging methods provide a means to characterize the heterogeneous and multiscale nature of these diseases by providing a wealth of temporally and spatially resolved data on their development and response to therapies (e.g., cancer architecture, mechanics, and vascularity; cancer cell mobility and proliferation; drug transport and effects). These multimodal, multiscale datasets can be exploited to constrain biophysical models of cancer growth and treatment response both in preclinical and clinical settings. These models can then be leveraged to test hypotheses, produce individualized cancer forecasts to guide clinical decision-making, and, ultimately, to design optimized therapies. The overall goal of this minisymposium is to provide a forum to present and discuss recent developments in data-informed computational models and methods for predicting cancer growth and treatment response, with special focus on the following research areas: (i) biology-based mechanistic models of cancer growth and treatment *in vitro* and *in vivo*; (ii) computational methods for model initialization, parameterization, and patient-specific simulation; (iii) model-oriented, personalized optimization of treatment regimens; (iv) uncertainty quantification and model selection methods; (v) hybrid strategies combining machine learning and mechanistic modelling; and (vi) digital twins in clinical oncology.

REFERENCES

- [1] G. Lorenzo, D.A. Hormuth II, A.M. Jarrett, *et al.*, “Quantitative In Vivo Imaging to Enable Tumour Forecasting and Treatment Optimization”. In: Balaz, I., Adamatzky, A. (eds), *Cancer, Complexity, Computation*, **46**, 55-97, Springer Cham, (2022).
- [2] M. Alber, A. Buganza Tepole, W.R. Cannon, *et al.*, “Integrating machine learning and multiscale modelling - perspectives, challenges, and opportunities in the biological, biomedical, and behavioral sciences”, *npj Digit. Med.*, **2**, 115, (2019).